A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 add-on to Metformin With Additional 28-week Open-label Treatment to Evaluate the Safety in T2DM Subjects
Latest Information Update: 02 Aug 2022
At a glance
- Drugs Dorzagliatin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DAWN
- Sponsors Hua Medicine
- 07 Jun 2022 Results of post hoc analysis of two phase III clinical trials (NCT03173391 and NCT03141073), evaluating the correlation between glycemic control and the restoration effect of glucokinase activator on beta cell cell function presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 01 May 2022 Results published in the Nature Medicine
- 29 Jun 2021 Results assessing the efficacy and safety of dorzagliatin add-on to metformin in T2D patients in a 52-Week, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.